Reversible myelofibrosis secondary to systemic lupus erythematosus.

Autor:	Rama Krishna Reddy MM; Department of Medicine, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, Mangalore, Karnataka, India., Boloor A; Department of Medicine, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, Mangalore, Karnataka, India archith.boloor@manipal.edu., Thomas NK; Gastroenterology and Hepatology, St Luke's Hospital, Pathanamthitta, Kerala, India.
Jazyk:	angličtina
Zdroj:	BMJ case reports [BMJ Case Rep] 2023 Aug 17; Vol. 16 (8). Date of Electronic Publication: 2023 Aug 17.
DOI:	10.1136/bcr-2023-255229
Abstrakt:	Pancytopenia due to systemic lupus erythematosus (SLE) is rarely reported, and among those reported, it is mostly due to immunologically mediated cell destruction. Pancytopenia due to bone marrow fibrosis secondary to SLE is an extremely rare entity. Myelofibrosis secondary to SLE per se is reported only in 21 cases in the literature. Ours probably is the 22nd case report on SLE with myelofibrosis. Primary presentation of SLE with bleeding manifestation is also a rare phenomenon. Partial to complete regression of myelofibrosis is noted following treatment in secondary myelofibrosis caused by SLE. We report a case of a woman in her late 40s who presented to us with bleeding manifestations of petechial rash and menorrhagia, which on further evaluation showed pancytopenia due to myelofibrosis secondary to SLE. Our case underlines multiple features like primary bleeding manifestation and regression of myelofibrosis following treatment which is rarely reported in association with SLE. Competing Interests: Competing interests: None declared. (© BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu